MedTrace Logo

Efficacy and Safety of Mirabegron Versus Oxybutynin After Posterior Urethral Valve Ablation

NCT07668232 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-06-29

No results posted yet for this study

Summary

Posterior urethral valve is the main cause of bladder outlet obstruction in male infants and the most common cause of obstructive uropathy leading to chronic renal failure and end-stage renal disease in children.The incidence of posterior urethral valve is approximately 1:7,000-8,000 live births.

Conditions

  • Posterior Urethral Valve

Interventions

DRUG

Mirabegron

To assess the efficacy and the safety of Mirabegron and Oxybutynin drugs after posterior urethral valve ablation regarding: the Effect on upper and lower urinary tract and Febrile UTI recurrence.

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Ahmad Abolyosr Mohamed, Professor · Professor of Urology, Faculty of medicine,South Valley University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-12-15
Completion
2025-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07668232 on ClinicalTrials.gov